The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
出版年份 2023 全文链接
标题
The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
作者
关键词
-
出版物
Virology Journal
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-11-03
DOI
10.1186/s12985-023-02220-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
- (2022) ChuanLiang Cui et al. Journal for ImmunoTherapy of Cancer
- Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
- (2022) Alexander N. Shoushtari et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
- (2022) Jason A. Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
- (2022) Julia Katharina Schwarze et al. Journal for ImmunoTherapy of Cancer
- Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
- (2022) Song Y Park et al. Journal for ImmunoTherapy of Cancer
- T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model
- (2021) Emma H. A. Stahlie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
- (2021) Julia Maria Ressler et al. Journal for ImmunoTherapy of Cancer
- Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
- (2021) Josep Malvehy et al. Journal for ImmunoTherapy of Cancer
- The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
- (2021) Matthew J. Page et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma
- (2021) Robert H. I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors in melanoma
- (2021) Matteo S Carlino et al. LANCET
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
- (2021) R. Dummer et al. NATURE MEDICINE
- Oncolytic Viruses for the Treatment of Metastatic Melanoma
- (2020) Megan H. Trager et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec
- (2020) Claire Audrey-Bayan et al. MELANOMA RESEARCH
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
- (2020) Sreya Bagchi et al. Annual Review of Pathology-Mechanisms of Disease
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
- (2019) Robert H.I. Andtbacka et al. EBioMedicine
- Design and application of oncolytic viruses for cancer immunotherapy
- (2019) Erkko Ylösmäki et al. CURRENT OPINION IN BIOTECHNOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
- (2018) Lillian Sun et al. Journal for ImmunoTherapy of Cancer
- A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients
- (2018) Margarita Garcia et al. HUMAN GENE THERAPY
- The Role of Oncolytic Viruses in the Treatment of Melanoma
- (2018) Claire-Audrey Y. Bayan et al. Current Oncology Reports
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
- (2018) Carmela Passaro et al. CLINICAL CANCER RESEARCH
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
- (2016) Praveen K. Bommareddy et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma
- (2016) B. Curti et al. ANNALS OF ONCOLOGY
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
- (2016) Robert H. I. Andtbacka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunovirotherapy with measles virus strains in combination with anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment
- (2016) Jayson Hardcastle et al. NEURO-ONCOLOGY
- Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
- (2016) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Oncolytic Viruses: Therapeutics With an Identity Crisis
- (2016) Caroline J. Breitbach et al. EBioMedicine
- Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Resultsin vitro, in rodents and in humans
- (2015) Simona Bramante et al. INTERNATIONAL JOURNAL OF CANCER
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- (2014) James Larkin et al. LANCET ONCOLOGY
- Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma
- (2012) Evanthia Galanis et al. MOLECULAR THERAPY
- A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
- (2011) Tae-Ho Hwang et al. MOLECULAR THERAPY
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started